[
  {
    "ts": null,
    "headline": "McKesson Corp. stock underperforms Thursday when compared to competitors",
    "summary": "McKesson Corp. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=dbf607b3b3af9ae25736a220cc8f44620ab1f56836cdba7203fee9b7be7556b2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760632740,
      "headline": "McKesson Corp. stock underperforms Thursday when compared to competitors",
      "id": 137140709,
      "image": "",
      "related": "MCK",
      "source": "MarketWatch",
      "summary": "McKesson Corp. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=dbf607b3b3af9ae25736a220cc8f44620ab1f56836cdba7203fee9b7be7556b2"
    }
  },
  {
    "ts": null,
    "headline": "Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US",
    "summary": "DETROIT, October 16, 2025--Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in partnership with Handa Therapeutics, LLC, and will be exclusively available through specialty pharmacy Onco360® with a specialty distribution network from McKesson, Cencora, and Cardinal Health.",
    "url": "https://finnhub.io/api/news?id=af5bcbe3e88f76306f1ead52f0151a323c3a2131485bff5935234082c9a03449",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760619600,
      "headline": "Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US",
      "id": 137104649,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MCK",
      "source": "Yahoo",
      "summary": "DETROIT, October 16, 2025--Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in partnership with Handa Therapeutics, LLC, and will be exclusively available through specialty pharmacy Onco360® with a specialty distribution network from McKesson, Cencora, and Cardinal Health.",
      "url": "https://finnhub.io/api/news?id=af5bcbe3e88f76306f1ead52f0151a323c3a2131485bff5935234082c9a03449"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights UBS, Newmont, McKesson and The Cato",
    "summary": "Zacks spotlights UBS, Newmont, McKesson, and Cato, four companies showing strong performance across finance, gold mining, healthcare distribution, and retail.",
    "url": "https://finnhub.io/api/news?id=fbad80e76c992f88d783a344e2af2645f7101dfc8960efc2b27bf0e6a7475b63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760601540,
      "headline": "The Zacks Analyst Blog Highlights UBS, Newmont, McKesson and The Cato",
      "id": 137104646,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MCK",
      "source": "Yahoo",
      "summary": "Zacks spotlights UBS, Newmont, McKesson, and Cato, four companies showing strong performance across finance, gold mining, healthcare distribution, and retail.",
      "url": "https://finnhub.io/api/news?id=fbad80e76c992f88d783a344e2af2645f7101dfc8960efc2b27bf0e6a7475b63"
    }
  },
  {
    "ts": null,
    "headline": "McKesson Valuation in Focus After Record Five Year Share Price Surge",
    "summary": "If you’re eyeing McKesson’s stock and wondering whether now is the right time to buy, hold, or cash in, you’re not alone. The company has been on quite a ride, and there’s plenty of chatter about its long-term value. In just the past week, McKesson’s price has climbed 4.8%, and in the last month it’s surged by a compelling 12.7%. Looking further back, the returns are even more impressive: 39.9% year-to-date, 55.7% over the last year, and a remarkable 435.3% over the past five years. Those...",
    "url": "https://finnhub.io/api/news?id=3a0e3f3dbf93db64a2d761aedea954f67f9ebccd3008269a82d37dbf44d8e3bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760576876,
      "headline": "McKesson Valuation in Focus After Record Five Year Share Price Surge",
      "id": 137102132,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MCK",
      "source": "Yahoo",
      "summary": "If you’re eyeing McKesson’s stock and wondering whether now is the right time to buy, hold, or cash in, you’re not alone. The company has been on quite a ride, and there’s plenty of chatter about its long-term value. In just the past week, McKesson’s price has climbed 4.8%, and in the last month it’s surged by a compelling 12.7%. Looking further back, the returns are even more impressive: 39.9% year-to-date, 55.7% over the last year, and a remarkable 435.3% over the past five years. Those...",
      "url": "https://finnhub.io/api/news?id=3a0e3f3dbf93db64a2d761aedea954f67f9ebccd3008269a82d37dbf44d8e3bb"
    }
  }
]